Trial Profile
A study evaluating efficacy of Lobeglitazone and clinical predictive markers responsible for the glycemic response of lobeglitazone.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jan 2018
Price :
$35
*
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jan 2018 New trial record
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation